Product Images Irinotecan Hydrochloride

This is a comparison study between second-line irinotecan chemotherapy and best supportive care (BSC) for cancer. The graph shows the survival rates of both treatments over a median follow-up period of 13 months. The results indicate that irinotecan had a significantly better survival rate compared to BSC (p-value of 0.0001).*

and infusional S-FU were compared in Study 8 to evaluate their effectiveness as second-line treatment for patients. The figure shows the survival rates and median follow-up time of 127 patients who received Irinotecan and 129 patients who received infusional S-FU. Median survival was 108 months for Irinotecan and 85 months for S-FU.*

Each mL of the product contains 20 mg of Irinotecan Hydrochloride, USP Tinydrate. It is stored at a temperature between 20° to 25°C (68° t0 77°F). Ensure protection from light and freezing. The product comes in a 2 mL Single-Use Vial and is intended for intravenous use only after being diluted. The product is sterile, nonpyrogenic, and free from preservatives. The package insert contains information regarding the usual dosage, and caution should be exercised as it is a cytotoxic agent. The manufacturer is AREVA Pharmaceuticals, Inc., located in Geometown, 47122, and the distributor is Cipla Ltd, AoV s o Phamaceuticds, e. The rest of the text is not available.*

This is a medication named Inotecan Hydrochloride Trihydrate. It comes in a single-use vial of 5ml and each mL contains 20mg of the medication. The recommended storage temperature is 20°C to 25°C, and it should be protected from light and freezing. It is for intravenous use only and is a cytotoxic agent. The package warns that the closure is not made of natural rubber latex. The package contains further information about the product. Manufacturers of the medication are AREVA Pharmaceuticals Inc. and The Ehrlich Group. The text includes some errors.*